Macro Dynamics - The Ministry of Industry and Information Technology has revised the management measures for cultivating high-quality small and medium-sized enterprises (SMEs), now including technology-based SMEs in the cultivation scope for the first time. The new measures aim to enhance the recognition standards and management service mechanisms, ensuring the quality of cultivated enterprises. Since the start of the 14th Five-Year Plan, 17,600 specialized and innovative "little giant" enterprises have been cultivated, leading to over 140,000 specialized and innovative SMEs and more than 600,000 technology and innovation-based SMEs [2]. Financial Institutions - Aiko Micro has initiated the A-share listing guidance, with CITIC Jianan Securities as the advisory institution. The company, founded in 2018 and headquartered in Shanghai, specializes in high-end chip design for wireless communication and has no single shareholder holding more than 30% of the shares [7]. Market Data - On January 16, U.S. stock indices experienced slight declines, with the Nasdaq down 0.06%, the Dow down 0.17%, and the S&P 500 down 0.06%. However, semiconductor stocks saw gains, with Micron Technology rising over 7% and the Philadelphia Semiconductor Index increasing by 1.15%. For the week, the Dow fell 0.29%, the Nasdaq fell 0.66%, and the S&P 500 fell 0.38%, while the Philadelphia Semiconductor Index rose 3.78% [8]. Company Dynamics - Xinghe Power issued an apology following the failure of its commercial rocket, the "Goddess Star No. 2," during its first flight test. The company is currently investigating the cause of the failure and is committed to ensuring the success of future launch missions [9][10]. - Zhuhai Wanda Commercial Management has appointed Xu Fen as the new CEO, replacing Huang Dewei. Chen Qi has been appointed as the COO, with Xu no longer holding that position [11]. - The parent company of Banmu Huatian, Shandong Huawutang Cosmetics Co., has submitted a listing application to the Hong Kong Stock Exchange. The company expects its adjusted net profit to increase by 249.4% from RMB 23.7 million in 2023 to RMB 82.8 million in 2024 [12].

Core Viewpoint - China's foreign trade demonstrates resilience and vitality, achieving a record high in total import and export value in 2025, maintaining its position as the world's largest goods trading nation [1][2]. Group 1: Trade Performance - In 2025, China's total import and export value reached 45.47 trillion yuan, a year-on-year increase of 3.8%, marking nine consecutive years of growth [1]. - Exports amounted to 26.99 trillion yuan, growing by 6.1%, while imports were 18.48 trillion yuan, with a modest increase of 0.5% [1]. - The growth in high-tech product exports was notable, with a year-on-year increase of 13.2%, contributing 2.4 percentage points to overall export growth [2]. Group 2: Import Trends - China maintained its status as the world's second-largest import market for 17 consecutive years, with imports reaching a historical high in 2025 [4]. - Import growth was driven by a recovering economy, with a continuous increase in imports for three consecutive quarters starting from Q2 [4]. - The 8th China International Import Expo saw record participation, with intended transaction amounts exceeding 80 billion USD [4]. Group 3: Trade Partnerships - China's trade partnerships expanded significantly, becoming a major trading partner for over 160 countries and regions, an increase of more than 20 since 2020 [6]. - Trade with ASEAN countries and Central Asian nations saw substantial growth, with imports from these regions increasing by 3.9% and over 1 billion USD in trade volume, respectively [6][7]. - In 2025, trade with countries involved in the Belt and Road Initiative reached 23.6 trillion yuan, growing by 6.3%, which is 2.5 percentage points higher than the overall trade growth rate [7].

Group 1 - The core viewpoint of the article is that Shandong Huawutang Cosmetics Co., Ltd., the parent company of Banmu Huatian, has submitted a listing application to the Hong Kong Stock Exchange with CITIC Securities as the sole sponsor [1] - The company’s adjusted net profit is projected to increase by 249.4% from RMB 23.7 million in 2023 to RMB 82.8 million in 2024 [1] - For the nine months ending September 30, 2024, the adjusted net profit is expected to rise by 197.2% from RMB 49.7 million to RMB 147.7 million in the same period of 2025 [1]

转自：新华社 《卫报》报道，劳德与特朗普曾是同学，相识逾60年，在特朗普频频放话要得到格陵兰岛的同时，劳德 已开始在格陵兰岛布局商业投资。 博尔顿在特朗普首个总统任期内担任总统国家安全事务助理。但因与特朗普意见不合，他就任一年多即 遭解职。博尔顿在2020年出版的回忆录中批评特朗普的外交政策和政府方针。特朗普则指责博尔顿的回 忆录"泄密"。2025年10月，博尔顿被起诉，罪名包括非法存储和传输机密信息等。（林芮竹） 博尔顿接受该报采访时说，特朗普在首个任期内曾将他叫到白宫办公室，称"一名知名商人建议美国购 买格陵兰岛"。博尔顿随后得知，这名商人是特朗普的朋友、美国化妆品巨头雅诗兰黛集团的继承人劳 德。 劳德提出这一建议后，特朗普政府开始研究加强美国在格陵兰岛影响力的方法。特朗普再次当选总统后 旧事重提。按照博尔顿的说法，特朗普"往往将朋友提供的零散信息视为真理，且很难动摇他的想法"。 新华社北京1月17日电 英国《卫报》15日报道，美国总统特朗普的前国家安全事务助理约翰·博尔顿透 露，特朗普对格陵兰岛的垂涎，源自美国亿万富翁罗纳德·劳德的"建议"。 ...

Core Viewpoint - A-share listed companies are actively engaging in shareholder return activities, utilizing methods beyond cash dividends, such as offering products, services, discount coupons, or exclusive rights, with mixed market performance but overall outpacing the CSI 300 index [1] Group 1: Shareholder Return Activities - Approximately 130 companies have shown varied market performance, with some adopting creative ways to reward shareholders [1] - Companies are not only providing gifts but are also formulating future dividend plans, with 10 companies announcing shareholder return strategies for the next three years [1] Group 2: Dividend Plans and Performance - The top performers in terms of stock price increase since 2025 include Haoen Qidian (301488) with a rise of 205.66%, Shuiyang Co. (300740) at 87.59%, and Huasheng Co. (600156) at 69.18% [3] - Specific dividend plans include: - Haoen Qidian: Minimum 10% of distributable profit annually from 2025 to 2027 [3] - Shuiyang Co.: Cash dividends not less than 10% of distributable profit annually from 2025 to 2027 [3] - Huasheng Co.: Cumulative cash distribution of at least 30% of the average distributable profit over the last three years from 2026 to 2028 [3] - Other companies like Gais Food (36.36%) and Bona Film (34.26%) also have significant dividend commitments [3]

Company Dynamics - The company announced on January 15 that its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" has been approved as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness through a recombinant collagen and hyaluronic acid composite solution [1] - The approval of this product is expected to further expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [1] Comments - The approval of the world's first recombinant collagen and hyaluronic acid composite solution for improving cheek smoothness represents the second medical aesthetic license obtained by the company [2] - The company plans to steadily advance the product's market launch and promotion through a diverse product portfolio, comprehensive channel network, and refined brand operations, aiming to strengthen its leading market position in the health and beauty sector [2] Future Prospects - The company has a rich pipeline of aesthetic medicine products, with the cross-linked neck wrinkle product having received national priority review qualification, and the cross-linked nasolabial fold product progressing smoothly [2] - The successful approval of the first two aesthetic products has validated the company's technological leadership and safety, with strong channel resources and operational experience expected to facilitate the rollout of future products [2] Cosmetics Product Matrix and Channel Expansion - The company has a clear plan for its cosmetics product matrix and channel expansion, with a rich reserve of new products, including multiple new offerings from the 可复美胶原修护, 焦点, and 秩序 series planned for launch [2] - The company is also upgrading its 可丽金 brand and plans to introduce new products by 2026, while collaborating with key influencers like Li Jiaqi to enhance marketing efforts [2] - The company aims to strengthen its online presence through influencer partnerships and expand its offline coverage in cinema lines, OTC, and CS/KA channels, as well as its own store layout [2] Profit Forecast and Valuation - The company maintains its net profit forecast for 2025-2026 and introduces a net profit estimate of 2.4 billion for 2027, with the current stock price corresponding to a 16x and 14x P/E for 2026-2027 [2] - The company maintains an outperform rating and a target price of 56 HKD, corresponding to a 25x and 23x P/E for 2026-2027, indicating a potential upside of 55% [2]

Core Viewpoint - The company Mao Ge Ping (01318) has received a filing notice from the China Securities Regulatory Commission regarding the implementation of full circulation of H-shares, effective from January 13, 2026 [1] Group 1 - The company has completed the filing for a total of 228 million unlisted shares for H-share full circulation with the China Securities Regulatory Commission [1] - The filing notice is valid for 12 months from January 13, 2026 [1] - The company will apply to the Stock Exchange of Hong Kong for approval of the related H-share listing and trading [1]

Group 1 - Shandong Huawutang Cosmetics Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange [1] - The exclusive sponsor for the listing is CITIC Securities [1]

Group 1 - Shandong Huawutang Cosmetics Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange [1]

Core Viewpoint - Shandong Huawutang Cosmetics Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor, indicating a significant step towards public offering in the cosmetics sector [1] Company Overview - Huawutang is recognized as a rapidly growing Chinese skincare and personal care brand, known for its multi-category expansion and strong market presence [1] - The company has evolved from a single star product to a comprehensive product matrix that includes body, hair, and facial care, establishing itself as a leading domestic brand in multiple categories within the Chinese skincare and personal care market [1] Market Position - According to Frost & Sullivan, Huawutang is projected to be the leading domestic brand in body lotion, body scrub, and facial cleansing mousse by retail sales in 2024 [1]